Cargando…

Hierarchically porous, and Cu- and Zn-containing γ-AlOOH mesostrands as adjuvants for cancer immunotherapy

Alum is the only licensed adjuvant by Food and Drug Administration of USA used in many human vaccines and has excellent safety record in clinical applications. However, alum hardly induces T helper 1 (Th1) immune responses that are required for anti-tumor immunity. In the present study, we fabricate...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Xia, Shenashen, Mohamed A., Wang, Xiupeng, Ito, Atsuo, Taniguchi, Akiyoshi, EI-Safty, Sherif A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5711866/
https://www.ncbi.nlm.nih.gov/pubmed/29196724
http://dx.doi.org/10.1038/s41598-017-12446-9
_version_ 1783283104274710528
author Li, Xia
Shenashen, Mohamed A.
Wang, Xiupeng
Ito, Atsuo
Taniguchi, Akiyoshi
EI-Safty, Sherif A.
author_facet Li, Xia
Shenashen, Mohamed A.
Wang, Xiupeng
Ito, Atsuo
Taniguchi, Akiyoshi
EI-Safty, Sherif A.
author_sort Li, Xia
collection PubMed
description Alum is the only licensed adjuvant by Food and Drug Administration of USA used in many human vaccines and has excellent safety record in clinical applications. However, alum hardly induces T helper 1 (Th1) immune responses that are required for anti-tumor immunity. In the present study, we fabricated hierarchical copper- and zinc- buds dressing γ-AlOOH mesostrands (Cu- and Zn-AMSs) with randomly wrinkled morphology, mesoscale void- or cave-like pockets, high-exposed surface coverage sites, and positive charge streams in saline. We confirmed that Cu- and Zn-AMSs promoted intracellular uptake of model cancer antigen (ovalbumin, OVA) by THP-1-differentiated macrophage-like cells in vitro. Moreover, Cu- and Zn-AMSs enhanced maturation and cytokine release of bone marrow dendritic cells in vitro. In vivo study demonstrated that Cu- and Zn-AMSs markedly induced anti-tumor-immunity and enhanced CD(4) (+) and CD(8) (+) T cell populations in splenocytes of mice. These findings demonstrated that hierarchical copper- and zinc- buds dressing γ-AlOOH mesostrands, which are oriented in randomly wrinkled matrice, are suitable platforms as novel adjuvants for cancer immunotherapy.
format Online
Article
Text
id pubmed-5711866
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-57118662017-12-06 Hierarchically porous, and Cu- and Zn-containing γ-AlOOH mesostrands as adjuvants for cancer immunotherapy Li, Xia Shenashen, Mohamed A. Wang, Xiupeng Ito, Atsuo Taniguchi, Akiyoshi EI-Safty, Sherif A. Sci Rep Article Alum is the only licensed adjuvant by Food and Drug Administration of USA used in many human vaccines and has excellent safety record in clinical applications. However, alum hardly induces T helper 1 (Th1) immune responses that are required for anti-tumor immunity. In the present study, we fabricated hierarchical copper- and zinc- buds dressing γ-AlOOH mesostrands (Cu- and Zn-AMSs) with randomly wrinkled morphology, mesoscale void- or cave-like pockets, high-exposed surface coverage sites, and positive charge streams in saline. We confirmed that Cu- and Zn-AMSs promoted intracellular uptake of model cancer antigen (ovalbumin, OVA) by THP-1-differentiated macrophage-like cells in vitro. Moreover, Cu- and Zn-AMSs enhanced maturation and cytokine release of bone marrow dendritic cells in vitro. In vivo study demonstrated that Cu- and Zn-AMSs markedly induced anti-tumor-immunity and enhanced CD(4) (+) and CD(8) (+) T cell populations in splenocytes of mice. These findings demonstrated that hierarchical copper- and zinc- buds dressing γ-AlOOH mesostrands, which are oriented in randomly wrinkled matrice, are suitable platforms as novel adjuvants for cancer immunotherapy. Nature Publishing Group UK 2017-12-01 /pmc/articles/PMC5711866/ /pubmed/29196724 http://dx.doi.org/10.1038/s41598-017-12446-9 Text en © The Author(s) 2017 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Article
Li, Xia
Shenashen, Mohamed A.
Wang, Xiupeng
Ito, Atsuo
Taniguchi, Akiyoshi
EI-Safty, Sherif A.
Hierarchically porous, and Cu- and Zn-containing γ-AlOOH mesostrands as adjuvants for cancer immunotherapy
title Hierarchically porous, and Cu- and Zn-containing γ-AlOOH mesostrands as adjuvants for cancer immunotherapy
title_full Hierarchically porous, and Cu- and Zn-containing γ-AlOOH mesostrands as adjuvants for cancer immunotherapy
title_fullStr Hierarchically porous, and Cu- and Zn-containing γ-AlOOH mesostrands as adjuvants for cancer immunotherapy
title_full_unstemmed Hierarchically porous, and Cu- and Zn-containing γ-AlOOH mesostrands as adjuvants for cancer immunotherapy
title_short Hierarchically porous, and Cu- and Zn-containing γ-AlOOH mesostrands as adjuvants for cancer immunotherapy
title_sort hierarchically porous, and cu- and zn-containing γ-alooh mesostrands as adjuvants for cancer immunotherapy
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5711866/
https://www.ncbi.nlm.nih.gov/pubmed/29196724
http://dx.doi.org/10.1038/s41598-017-12446-9
work_keys_str_mv AT lixia hierarchicallyporousandcuandzncontaininggaloohmesostrandsasadjuvantsforcancerimmunotherapy
AT shenashenmohameda hierarchicallyporousandcuandzncontaininggaloohmesostrandsasadjuvantsforcancerimmunotherapy
AT wangxiupeng hierarchicallyporousandcuandzncontaininggaloohmesostrandsasadjuvantsforcancerimmunotherapy
AT itoatsuo hierarchicallyporousandcuandzncontaininggaloohmesostrandsasadjuvantsforcancerimmunotherapy
AT taniguchiakiyoshi hierarchicallyporousandcuandzncontaininggaloohmesostrandsasadjuvantsforcancerimmunotherapy
AT eisaftysherifa hierarchicallyporousandcuandzncontaininggaloohmesostrandsasadjuvantsforcancerimmunotherapy